what drives us

At Chimerix, we’re committed to driving the development of groundbreaking medicines designed to protect immunocompromised patients from potentially deadly viral infections.

The Need for Antiviral Protection

  • 81,000
    Number of stem cell transplants performed every year worldwide1
  • 66%
    Proportion (or percentage) of allogeneic stem cell transplant recipients who have 2 or more dsDNA viral infections2
  • 18
    Percentage of pediatric stem cell transplant patients who experience adenovirus disease in the first 100 days following transplant3
  • 50-80%
    Estimated mortality rate associated with disseminated adenovirus disease among stem cell transplant recipients if left untreated4
  • 0
    Number of approved therapies for the treatment of adenovirus5

disease areas of expertise


Adenovirus, which causes the common cold in people with healthy immune systems, can lead to life-threatening infections in immunocompromised people.4

Cytomegalovirus (CMV)

Cytomegalovirus (CMV) is a member of the herpesvirus family and remains a significant cause of viral infections in transplant recipients.

BK Virus

The majority of adults have been infected with BK virus6, which can reactivate and cause severe complications in stem cell transplant and solid organ transplant recipients, and other immunocompromised individuals. 7


Though smallpox has been officially eradicated, it remains a threat in cases of bioterror or as a potential bioterror weapon.


Noroviruses are the most common cause of acute gastroenteritis worldwide. In immunocompromised adults, norovirus infection can become chronic and persist for weeks to years.8